Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Briacell Therap stock logo
BCTX
Briacell Therap
$0.80
-4.0%
$2.88
$0.69
$29.40
$5.41M1.27748,170 shs1.55 million shs
Equillium, Inc. stock logo
EQ
Equillium
$0.42
-1.4%
$0.36
$0.27
$1.50
$14.83M1.86470,170 shs284,730 shs
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
$3.31
$1.31
$20.89
$2.91M0.76261,432 shs245,100 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Briacell Therap stock logo
BCTX
Briacell Therap
0.00%-60.48%-74.41%-81.39%-94.22%
Equillium, Inc. stock logo
EQ
Equillium
0.00%+18.60%+28.71%-12.15%-55.21%
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Briacell Therap stock logo
BCTX
Briacell Therap
1.4556 of 5 stars
3.52.00.00.00.60.00.6
Equillium, Inc. stock logo
EQ
Equillium
2.2127 of 5 stars
3.24.00.00.00.61.70.6
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Briacell Therap stock logo
BCTX
Briacell Therap
3.00
Buy$32.003,908.52% Upside
Equillium, Inc. stock logo
EQ
Equillium
2.33
Hold$3.00622.72% Upside
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MDVL, BCTX, and EQ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2025
Briacell Therap stock logo
BCTX
Briacell Therap
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/A($2.20) per shareN/A
Equillium, Inc. stock logo
EQ
Equillium
$30.41M0.49N/AN/A$0.54 per share0.77
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
$43.33M0.00N/AN/A$13.01 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Briacell Therap stock logo
BCTX
Briacell Therap
-$4.79M-$8.32N/AN/AN/AN/A-479.97%-182.26%N/A
Equillium, Inc. stock logo
EQ
Equillium
-$8.07M-$0.39N/AN/AN/A-19.62%-74.34%-46.75%8/6/2025 (Estimated)
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
-$47.62M-$28.72N/AN/AN/A-192.97%-218.10%-103.45%N/A

Latest MDVL, BCTX, and EQ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q1 2025
Equillium, Inc. stock logo
EQ
Equillium
-$0.1850N/AN/AN/AN/AN/A
6/13/2025Q3 2025
Briacell Therap stock logo
BCTX
Briacell Therap
-$1.76-$1.64+$0.12-$1.64N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/AN/A
Equillium, Inc. stock logo
EQ
Equillium
N/AN/AN/AN/AN/A
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Briacell Therap stock logo
BCTX
Briacell Therap
N/A
3.41
3.41
Equillium, Inc. stock logo
EQ
Equillium
N/A
2.70
2.70
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Briacell Therap stock logo
BCTX
Briacell Therap
15.42%
Equillium, Inc. stock logo
EQ
Equillium
27.05%
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
N/A

Insider Ownership

CompanyInsider Ownership
Briacell Therap stock logo
BCTX
Briacell Therap
5.73%
Equillium, Inc. stock logo
EQ
Equillium
31.60%
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
1.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Briacell Therap stock logo
BCTX
Briacell Therap
86.78 million6.39 millionNo Data
Equillium, Inc. stock logo
EQ
Equillium
4035.72 million24.43 millionNot Optionable
MedAvail Holdings, Inc. stock logo
MDVL
MedAvail
2791.61 million1.59 millionNo Data

Recent News About These Companies

Delhi Bank Corp DWNX
US Stocks Mixed; Trimble Issues Weak Outlook
Medavail Holdings Inc (MDVL)
MedAvail Holdings Inc Ordinary Shares MDVL
MDVL, BACK and FTEL are among mid-day movers

New MarketBeat Followers Over Time

Media Sentiment Over Time

Briacell Therap stock logo

Briacell Therap NASDAQ:BCTX

$0.80 -0.03 (-3.98%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$0.81 +0.02 (+1.97%)
As of 07/18/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Equillium stock logo

Equillium NASDAQ:EQ

$0.42 -0.01 (-1.40%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$0.43 +0.01 (+3.35%)
As of 07/18/2025 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

MedAvail stock logo

MedAvail NASDAQ:MDVL

MedAvail Holdings, Inc., a technology-enabled retail pharmacy technology and services company, develops and commercializes self-service pharmacy, mobile application, and kiosk solutions in the United States and Canada. It offers a pharmacy technology solution, including the MedAvail MedCenter, which enables on-site pharmacy in medical clinics, retail store locations, employer sites with and without onsite clinics, and other location where onsite prescription dispensing is desired, as well as establishes an audio-visual connection to a live pharmacist enabling prescription drug dispensing to occur directly to a patient with real-time supervision by a pharmacist. The company is headquartered in Phoenix, Arizona. On February 2, 2024, MedAvail Holdings, Inc along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.